Revenue: As of FY2025 Q2, the actual value is USD 33.26 K.EPS: As of FY2025 Q2, the actual value is USD -0.15.EBIT: As of FY2025 Q2, the actual value is USD -1.47 M.<h3>Segment Revenue</h3><ul><li>Collaboration Revenue: $33,257 for the three months ended June 30, 2025, with no revenue in the comparable period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: $6,522 for the three months ended June 30, 2025.</li><li>Operating Expenses: Total operating expenses were $1,476,195 for the three months ended June 30, 2025, a decrease from $1,681,963 in the same period in 2024.</li><li>Net Loss: $1,448,729 for the three months ended June 30, 2025, compared to $1,611,646 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $3,230,098 for the six months ended June 30, 2025, compared to - $3,132,149 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $372,750 for the six months ended June 30, 2025, compared to $6,121,507 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company aims to utilize its bfLEAP™ AI/ML platform to improve drug development success rates and reduce costs, with a focus on strategic partnerships and collaborations.</li><li>Non-Core Business: The company plans to acquire rights to drugs at various development stages, using its AI/ML technology to advance these drugs and create value within approximately 30 months.</li><li>Liquidity Concerns: The company acknowledges substantial doubt about its ability to continue as a going concern without additional capital, which it plans to raise through equity sales, debt transactions, and collaborations.</li></ul>

BULLFROG AI HOLDINGS INC C/WTS EXP (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 33.26 K